CA2413045C - Expression system - Google Patents

Expression system Download PDF

Info

Publication number
CA2413045C
CA2413045C CA2413045A CA2413045A CA2413045C CA 2413045 C CA2413045 C CA 2413045C CA 2413045 A CA2413045 A CA 2413045A CA 2413045 A CA2413045 A CA 2413045A CA 2413045 C CA2413045 C CA 2413045C
Authority
CA
Canada
Prior art keywords
ser
asn
thr
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2413045A
Other languages
English (en)
French (fr)
Other versions
CA2413045A1 (en
Inventor
Ethel Diane Williamson
Julie Miller
Nicola Jane Walker
Leslie William James Baillie
Paula Thomson Holden
Helen Claire Flick-Smith
Helen Lisa Bullifent
Richard William Titball
Andrew William Topping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to CA002658217A priority Critical patent/CA2658217A1/en
Publication of CA2413045A1 publication Critical patent/CA2413045A1/en
Application granted granted Critical
Publication of CA2413045C publication Critical patent/CA2413045C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2413045A 2000-07-08 2001-07-06 Expression system Expired - Lifetime CA2413045C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002658217A CA2658217A1 (en) 2000-07-08 2001-07-06 Expression system

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0016702.3 2000-07-08
GBGB0016702.3A GB0016702D0 (en) 2000-07-08 2000-07-08 Expression system
PCT/GB2001/003065 WO2002004646A1 (en) 2000-07-08 2001-07-06 Expression system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002658217A Division CA2658217A1 (en) 2000-07-08 2001-07-06 Expression system

Publications (2)

Publication Number Publication Date
CA2413045A1 CA2413045A1 (en) 2002-01-17
CA2413045C true CA2413045C (en) 2016-06-21

Family

ID=9895205

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2413045A Expired - Lifetime CA2413045C (en) 2000-07-08 2001-07-06 Expression system
CA002658217A Abandoned CA2658217A1 (en) 2000-07-08 2001-07-06 Expression system

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002658217A Abandoned CA2658217A1 (en) 2000-07-08 2001-07-06 Expression system

Country Status (10)

Country Link
US (3) US7537771B2 (https=)
EP (2) EP1301606A1 (https=)
JP (2) JP2004502460A (https=)
CN (2) CN101012458A (https=)
AU (1) AU2007201553B8 (https=)
CA (2) CA2413045C (https=)
GB (1) GB0016702D0 (https=)
RU (2) RU2270865C2 (https=)
WO (1) WO2002004646A1 (https=)
ZA (1) ZA200210206B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
EP1575505A4 (en) * 2002-09-10 2007-01-24 Vical Inc CODON OPTIMIZATION-BASED POLYNUCLEOTIDE VACCINES AGAINST BACILLUS ANTHRACIS INFECTION
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1572977B1 (en) 2002-11-15 2010-03-03 Gen-Probe Incorporated Assay and compositions for detection of bacillus anthracis nucleic acid
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
FR2860005A1 (fr) * 2003-09-23 2005-03-25 Univ Aix Marseille Ii Methode de detection d'agents bacteriens ou viraux de bioterrorisme
WO2005030991A1 (fr) * 2003-09-23 2005-04-07 Universite De La Mediterranee (Aix-Marseille Ii) Methode de detection d’agents bacteriens ou viraux de bioterrorisme
GB0401036D0 (en) * 2004-01-17 2004-02-18 Royal Holloway University Of L Improvements in or relating to vaccination
US8101735B2 (en) 2004-06-16 2012-01-24 Health Protection Agency Preparation of protective antigen
US7355027B2 (en) * 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
CN100336908C (zh) * 2004-09-10 2007-09-12 中国人民解放军军事医学科学院微生物流行病研究所 一种制备重组炭疽保护性抗原的方法及其专用表达质粒
WO2006068647A1 (en) * 2004-12-20 2006-06-29 United States Army Medical Research And Materiel Command Internal positive control for probe-based nucleic acid molecule assays and methods of making and using thereof
GB0504940D0 (en) * 2005-03-10 2005-04-20 Secr Defence Vaccine formulation
EP1954307A4 (en) 2005-11-14 2009-12-02 Univ Maryland Biotech Inst ORAL VACCINES AGAINST MILZBRAND ON SALMONELLA BASE
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2008231063A (ja) * 2007-03-22 2008-10-02 Takano Foods Kk 納豆菌ワクチン
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
US8187611B2 (en) * 2009-10-29 2012-05-29 Albert Einstein College Of Medicine Of Yeshiva University Anti-peptide antibodies that cross react with protective antigen of Bacillus anthracis and uses thereof
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen
CN101798565B (zh) * 2010-02-26 2013-08-07 中国人民解放军军事医学科学院生物工程研究所 能在芽孢表面展示pa20蛋白的炭疽芽孢杆菌及其应用
RU2633508C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633504C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115433C1 (ru) * 1992-08-28 1998-07-20 Научно-исследовательский институт микробиологии МО РФ Вакцина сибиреязвенная комбинированная
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
RU2110575C1 (ru) * 1995-07-19 1998-05-10 Государственное Федеральное предприятие Государственный научный центр прикладной микробиологии Рекомбинантная плазмидная днк pro pf 5, определяющая синтез капсульного антигена fi возбудителя чумы и протективного антигена возбудителя сибирской язвы, и способ конструирования рекомбинантной плазмидной днк pro pf5
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system

Also Published As

Publication number Publication date
US20130164823A1 (en) 2013-06-27
RU2270865C2 (ru) 2006-02-27
EP1808489A1 (en) 2007-07-18
US9346860B2 (en) 2016-05-24
RU2004134341A (ru) 2006-05-10
US20030170263A1 (en) 2003-09-11
GB0016702D0 (en) 2000-08-23
AU2007201553B8 (en) 2010-06-03
CA2413045A1 (en) 2002-01-17
AU2007201553B2 (en) 2010-04-22
AU2007201553A1 (en) 2007-05-03
CN101012458A (zh) 2007-08-08
CN1322134C (zh) 2007-06-20
JP2004502460A (ja) 2004-01-29
WO2002004646A1 (en) 2002-01-17
EP1301606A1 (en) 2003-04-16
JP2012010706A (ja) 2012-01-19
US8313928B2 (en) 2012-11-20
CA2658217A1 (en) 2002-01-17
ZA200210206B (en) 2004-03-17
EP1808489B1 (en) 2016-03-23
AU6930501A (en) 2002-01-21
US20100266639A1 (en) 2010-10-21
RU2385348C2 (ru) 2010-03-27
CN1440459A (zh) 2003-09-03
US7537771B2 (en) 2009-05-26

Similar Documents

Publication Publication Date Title
CA2413045C (en) Expression system
Domann et al. Identification and characterization of a novel PrfA-regulated gene in Listeria monocytogenes whose product, IrpA, is highly homologous to internalin proteins, which contain leucine-rich repeats
CN101107361B (zh) 二硫桥连双链形式的蛋白质的重组表达
Hardie et al. In vitro activation of Escherichia coli prohaemolysin to the mature membrane‐targeted toxin requires HlyC and a low molecular‐weight cytosolic polypeptide
KR100338894B1 (ko) 백신조성물
Kansau et al. Heat shock proteins of Helicobacter pylori.
Ichikawa et al. Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis
US6777202B2 (en) Recombinant expression of S-layer proteins
CA2466156C (en) Ehrlichia disulfide bond formation proteins and uses thereof
CA1340577C (en) Recombinant systems for expressions of cholera b-subunit with the aid of foreign promoters and/or leader peptides
MXPA06000264A (es) Expresion recombinante de cisteina proteasa de streptococcus pyogenes y composiciones inmunogenicas de las mismas.
AU2001269305B2 (en) Expression system
AU2001269305A1 (en) Expression system
EP1373511A2 (en) Genes and proteins, and their uses
AU2001282299A1 (en) Genes and proteins, and their uses
US6342233B1 (en) Pseudomonas treatment composition and method
Himanen et al. The 20 kDa C-terminally truncated form of pertussis toxin subunit S1 secreted from Bacillus subtilis
JP2007510413A (ja) コレラ毒素のｂサブユニットのための発現システム
KR101911235B1 (ko) Stf2 재조합 단백질 발현용 유전자 카세트
Counc Outer membrane protein epitopes of Haemophilus influenzae; fusion protein expression in Escherichia coil: application to recombinant vaccine and antibody production, and in the production of reagents for diagnosis

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210706